Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG repeat expansion in the HTT gene, leading to mutant huntingtin protein aggregation. Treatment approaches include symptom management, disease-modifying therapies, and experimental interventions.
Motor Symptoms:
- Tetrabenazine: FDA-approved for chorea management
- Deutetrabenazine: FDA-approved for chorea (improved tolerability)
- Valbenazine: FDA-approved for chorea
- Amantadine: May reduce chorea (off-label)
- Antipsychotics: Haloperidol, olanzapine for chorea and behavioral symptoms
Cognitive Symptoms:
- Cholinesterase Inhibitors: Limited evidence for cognitive benefit
- Memantine: Investigational for cognitive symptoms
Psychiatric Symptoms:
- Antidepressants: SSRIs (citalopram, sertraline) for depression
- Antipsychotics: For irritability, aggression, psychosis
- Mood Stabilizers: Valproate, lamotrigine for mood lability
Antisense Oligonucleotides (ASOs):
- Tominersen (IONIS-HTTRx): Phase 3 trial showed no clinical benefit
- Other ASOs: In development targeting mutant HTT mRNA
RNAi Approaches:
- AAV-delivered RNAi: Preclinical/early clinical stages
- Coenzyme Q10: Large trial showed no significant benefit
- Creatine: Investigational for energy metabolism
- Minocycline: Anti-inflammatory; mixed results
- Laquinimod: Immunomodulatory; trials ongoing
- Stem Cell Transplantation: Early-stage research
- Gene Therapy: Viral vector delivery of therapeutic genes
- Small Molecule Aggreg inhibitors: In development
- Immunotherapy: Anti-mHTT antibodies under investigation
- Physical Therapy: Exercise, gait training, balance
- Occupational Therapy: Adaptive equipment, home modifications
- Speech Therapy: For dysarthria and swallowing
- High-Calorie Diets: Counteract weight loss
- Enteral Feeding: When oral intake becomes unsafe
- Counseling: For patients and families
- Support Groups: HD Society organizations
¶ Clinical Trials Landscape
Active areas of investigation include:
- Novel ASO formulations with better brain penetration
- CRISPR-based gene editing approaches
- Small molecules targeting specific pathological pathways
- Biomarker development for trial enrichment
The study of Treatment Approaches For Huntington'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Tabrizi SJ et al., Huntington disease (2019)
- Ross CA et al., Huntington's disease (2014)
- Frank S, Treatment of Huntington's disease (2014)
- Wild EJ et al., Huntington's disease (2023)
- Exercise programs: Tailored to maintain mobility and function
- Balance training: Fall prevention strategies
- Gait training: Adaptive techniques for chorea management
- Stretching routines: Spasticity and contracture prevention
- Home modifications: Safety adaptations for cognitive and motor deficits
- Assistive devices: Tools for daily living activities
- Energy conservation techniques: Managing fatigue
- Communication strategies: For dysarthria and cognitive-communication deficits
- Swallowing assessments: Prevent aspiration risk
- Augmentative communication devices: When speech becomes impaired
- Calorie-dense diets: Counteract weight loss from hypermetabolism
- Feeding strategies: Adaptive utensils, mealtime positioning
- PEG tube placement: When oral intake becomes unsafe
¶ Clinical Trials Landscape
- Gene-silencing therapies: Multiple ASO and RNAi approaches in development
- Protein aggregation modulators: Small molecules targeting mHTT aggregation
- Neurotrophic factors: BDNF delivery strategies
- Cell replacement therapies: embryonic stem cell-derived neurons
- Neurofilament light chain (NfL): Blood biomarker for disease progression [1]
- Mutant huntingtin (mHTT): CSF biomarker for therapeutic engagement
- Brain imaging: Volumetric MRI, PET tracers for mHTT
- Premanifest HD: Growing focus on preventive interventions
- Composite endpoints: Multiple outcome measures for heterogeneous symptoms
- Genetic stratification: Subgroup analyses by CAG repeat length
- Tabrizi SJ et al., Biomarkers in Huntington's disease (2023)
- Wild EJ et al., Molecular biomarkers for Huntington's disease (2022)
- Ross CA et al., Huntington's disease - toward disease-modifying therapies (2024)
- Landles C et al., The pathogenesis of Huntington's disease (2023)